Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-02-13

Tempus AI, Inc.

Tempus provides diagnostic testing plus data-driven software and services to support precision medicine and life-sciences R&D.

ai biotech healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From high-throughput testing to permissioned workflow platform

The upside case depends on proving that contracted life-sciences demand and embedded clinical workflows can scale faster than costs. Near-term audited reporting and 2026 operating leverage are the key de-risking steps.

Analysis

Thesis

Tempus can compound a defensible clinicogenomic data asset by scaling reimbursed testing and converting contracted life-sciences demand into repeatable analytics revenue; the non-linear upside comes if it becomes the auditable “default rail” for regulated oncology workflows (and outcomes-linked trial execution), not just a high-throughput lab.

Last Economy Alignment

AI makes “analysis” cheap; Tempus is positioned to sell trust + permissioned data rights + workflow defaultness, with compounding from longitudinal multimodal data refresh—gated by regulation and reimbursement.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.0x (from 5 most recent analyses)

Reasoning

A 5-year re-rating is plausible if Tempus proves it can turn diagnostic volume into a durable, renewal-like data/applications engine and then “lock in” value capture via embedded workflow and regulated claims. That combination can keep Tempus trading closer to platform-like diagnostics peers rather than commodity lab comps, even if margins stay in build mode due to continued reinvestment in evidence generation, integrations, and automation.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

Tempus’ upside is non-linear, but two constraints can bind: (1) regulatory/reimbursement throughput (what claims can be made, who pays, and at what rate), and (2) financing flexibility given debt and ongoing investment. Strategically, the key risk is value-capture: if workflow distribution sits with EMR vendors, large health systems, or CRO incumbents, Tempus may do the work while others capture the platform multiple.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

2026-02-10: Company announced Q4/FY2025 results date (Feb 24, 2026), increasing near-term repricing convexity.
Last 7–10 trading days: TEM saw notable volatility, consistent with high-beta healthcare AI/diagnostics peers into an earnings window.
Ongoing: Investor focus tightening on audited KPI definitions and conversion of contracted demand into recognized revenue.

Thesis update

n/a (same core thesis; incremental emphasis on near-term audit/outlook as the gating trust event).

Forecast update

Improved recent disclosure around contracted demand and near-term reporting cadence reduced the discount I apply to durability, but I keep a terminal-multiple haircut for financing/regulatory friction.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.49

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$87.92

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research